Licensing status

Publication and contact information

Infectious disease


HIV gp120

Nonhuman primate studies suggest combining the anti-HIV gp120 mAbs 3BNC117 and 10-1074 could help treat HIV infection. In rhesus macaques chronically infected with a pathogenic simian-human immunodeficiency virus (SHIV) with low CD4+ T cell levels, co-delivery of 3BNC117 and 10-1074 prolonged the time to virus rebound to three to five weeks, whereas individual antibodies only prolonged the time to virus rebound by four to seven days. Next steps include clinical trials with the antibodies to treat patients infected with HIV.

SciBX 6(46); doi:10.1038/scibx.2013.1325
Published online Dec. 5, 2013

Patent application filed; unlicensed

Shingai, M. et al. Nature; published online Oct. 30, 2013;
Contact: Malcolm A. Martin, National Institute of Allergy and Infectious Diseases, Bethesda, Md.